AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18271226
Drug: Routine diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine diabetic therapy with acupuncture at specific points (control group)
Trial: 15952402
Drug: Neridronate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate (25 mg monthly injection) + Calcium (500 mg daily) + Vitamin D (400 U daily)
Trial: 15952402
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg daily) + Vitamin D (400 U daily)
Trial: 7596123
Drug: Molsidomine retard
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine retard 8 mg
Trial: 1486070
Drug: 3% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% acyclovir ointment and 0.1% betamethasone (Betnesol) drops
Trial: 1486070
Drug: Acyclovir ointment
RxNorm normalized name: Acyclovir Ointment
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir ointment and matching placebo
Trial: 6489764
Drug: Co-dergocrine mesylate
RxNorm normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-dergocrine mesylate (Hydergine) 1.5 three times daily
Trial: 27729533
Drug: Reading intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reading intervention focusing on the malleability of reading abilities and praising effort; details on dosage and duration not available.
Trial: 27729533
Drug: Reading intervention;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading intervention; details on dosage and duration not available.
Trial: 22012861
Drug: Sugammadex 2
RxNorm normalized name: sugammadex 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2 mg kg(‐1) of corrected body weight (Group SUG)
Trial: 22012861
Drug: Neostigmine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.05 mg kg(‐1) of corrected body weight (Group NEO)
Trial: 15677779
Drug: PACCTS (Pro‐Active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACCTS (Pro‐Active Call Center Treatment Support)
Trial: 11865416
Drug: Lopinavir/Ritonavir (400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (400/100 mg or 400/200 mg twice daily)
Trial: 11865416
Drug: Lopinavir/Ritonavir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir plus Nevirapine (200 mg 2x/day) and nucleoside reverse-transcriptase inhibitors
Trial: 11865416
Drug: Lopinavir/Ritonavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir treatment
Trial: 7874950
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus NIPSV (n = 21)
Trial: 7874950
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n = 20)
Trial: 7874950
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus NIPSV (n = 17, subgroup with PaCO2 > 45 mm Hg)
Trial: 7874950
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n = 17, subgroup with PaCO2 > 45 mm Hg)
Trial: 2211567
Drug: Buspirone 5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 5-10 mg t.i.d. for 6 weeks
Trial: 2211567
Drug: Oxazepam 10-20
RxNorm normalized name: oxazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 10-20 mg t.i.d. for 6 weeks
Trial: 23905374
Drug: Salvianolate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvianolate (200 mg/day) with routine Western medical treatment
Trial: 24672935
Drug: Routine Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Western medical treatment (Control)
Trial: 19242322
Drug: Unfractioned heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractioned heparin (UFH)
Trial: 16542205
Drug: Talinolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol (100 mg daily)
Trial: 11522675
Drug: Hypoglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic clamp (blood glucose reduced to 54 mg/dl)
Trial: 11522675
Drug: Hyperinsulinemic-euglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic-euglycemic clamp (blood glucose maintained near 100 mg/dl)
Trial: 9233903
Drug: Mesterolone (MES)
RxNorm normalized name: mesterolone
DrugBank: Mesterolone (DB13587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesterolone (MES) 100 mg/d
Trial: 9233903
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE) 250 mg i.m./21 days
Trial: 9233903
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg crystalline testosterone (TPEL) subcutaneously implanted
Trial: 8502509
Drug: Ritalin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritalin (0.3 mg/kg per dose)
Trial: 3102211
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment group (TG) with CDP of 6 cm water pressure applied at birth by the nasopharyngeal route.
Trial: 29938412
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine 2% (Group A)
Trial: 18700624
Drug: Haemaccel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemaccel (10 ml/kg intravenously over 10‐15 minutes)
Trial: 18700624
Drug: Injection ephedrine
RxNorm normalized name: ephedrine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection ephedrine (0.2 mg/kg iv)
Trial: 18700624
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no study medication)
Trial: 15696985
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate topical gel 1% (CG)
Trial: 10548211
Drug: Dalteparin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (20 units/kg bolus, 10 units/kg/hr infusion)
Trial: 10548211
Drug: Heparin (2000-5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (2000-5000 units bolus, 10 units/kg/hr infusion, titrated to 70-80 secs aPTT)
Trial: 6301320
Drug: Cytomegalovirus immune
RxNorm normalized name: cytomegalovirus immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytomegalovirus immune globulin administered before and for 11 weeks after transplantation
Trial: 16935718
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT scans
Trial: 31664156
Drug: Buffered acidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered acidic saline solution (pH 5.2)
Trial: 31664156
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (pH 6)
Trial: 11528262
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide
Trial: 24560062
Drug: Ranolazine added
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine added to standard-of-care (SoC) treatment
Trial: 24560062
Drug: Standard-of-care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SoC) treatment alone
Trial: 22834720
Drug: Conservative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative care (IV epidural preload volume of <500 mLs continuing at an hourly rate of 75-100 mL/h)
Trial: 22834720
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (epidural preload volume of ≥500 mLs and an hourly rate >125 mL/h)
Trial: 19273551
Drug: Antioxidant group
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant group (1 g l-ascorbic acid, 400 IU alpha-tocopherol acetate, 600 mg alpha-lipoic acid in four divided doses)
Trial: 12383043
Drug: Fondaparinux sodium
RxNorm normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux sodium 10mg + aspirin 975mg
Trial: 10369196
Drug: Cyclophosphamide, dipyridamole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, dipyridamole, warfarin
Trial: 8537694
Drug: Levosulpiride (L)
RxNorm normalized name: L-377202
DrugBank: Levosulpiride (DB16021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride (L) 75 mg/day
Trial: 8537694
Drug: Metoclopramide (M)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (M) 30 mg/day
Trial: 2406218
Drug: Dipivefrin 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipivefrin 0.1% twice daily during the holiday
Trial: 2406218
Drug: Timolol therapy
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol therapy restored after holiday
Trial: 2406218
Drug: Dipivefrin-treated group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipivefrin-treated group (60 days treatment)
Trial: 28241070
Drug: Bisensory‐DBM with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisensory‐DBM with scented cream
Trial: 28241070
Drug: Multisensory‐DBM with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory‐DBM with scented cream associated with audiovisual material
Trial: 23485514
Drug: Lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid (1200 mg/day)
Trial: 18163196
Drug: Eptifibatide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (two 180 microg/kg boluses followed by infusion at 2.0 and 1.3 microg/kg/min for 24 and 48 h, respectively)
Trial: 18163196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treated without GP IIb‐IIIa antagonists)
Trial: 21455709
Drug: D-cycloserine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (125 mg)
Trial: 11159249
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of dextromethorphan given eight hourly
Trial: 9773893
Drug: NaCl-NaCitrate beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl-NaCitrate beverage (185 mEq x L(‐1) Na+, 283 mOsm x kg(‐1))
Trial: 9773893
Drug: NaCl-NaCitrate beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl-NaCitrate beverage (21.6 mEq x L(‐1) Na+, 365 mOsm x kg(‐1))
Trial: 2843314
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg/h)
Trial: 28522759
Drug: Ibuprofen (IB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (IB; 10 mg/kg)
Trial: 26226987
Drug: High-dose impact-loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose impact-loading (80 jumps per session)
Trial: 26226987
Drug: Moderate-dose impact-loading
RxNorm normalized name: IMPACT
DrugBank: Topramezone (DB14826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose impact-loading (40 jumps per session)
Trial: 14529447
Drug: Dartmouth-regimen combination
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dartmouth-regimen combination chemotherapy
Trial: 1090796
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent chemotherapy
Trial: 22240497
Drug: Pycnogenol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (200 mg/day) for 8 weeks
Trial: 22240497
Drug: Pycnogenol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (200 mg/day)
Trial: 18241647
Drug: Yiqing Shuangjie
RxNorm normalized name: SODIUM HYPOCHLORITE 6 g in 100 mL TOPICAL LIQUID [(Qiqing) Sodium Hypochlorite Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqing Shuangjie Capsule (treatment group A)
Trial: 18241647
Drug: Yiqing Shuangjie
RxNorm normalized name: SODIUM HYPOCHLORITE 6 g in 100 mL TOPICAL LIQUID [(Qiqing) Sodium Hypochlorite Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqing Shuangjie Tablet (treatment group B)
Trial: 18241647
Drug: Chaihuang Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaihuang Tablet and Yiqing Shuangjie Capsule analogues (control group)
Trial: 15763605
Drug: Combination oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oxycodone 5 mg/ibuprofen 400 mg
Trial: 9181183
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of synthetic steroids administered orally starting on day 8 of the menstrual cycle (group I)
Trial: 9181183
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of synthetic steroids administered orally starting on day 10 of the menstrual cycle (group II)
Trial: 11704703
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with nitrendipine (dihydropyridine calcium channel blocker)
Trial: 11704703
Drug: Nitrendipine monotherapy
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine monotherapy
Trial: 8500236
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment group
Trial: 20519346
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg rhTSH followed by a thyroid dose of 50 Gy
Trial: 18580042
Drug: BAS (BlastAssyst
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAS (BlastAssyst system containing L‐glutamine)
Trial: 10998833
Drug: Methylcobalamin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcobalamin 0.5 mg orally three times a day for 6 months
Trial: 10998833
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management (patient education, physical therapy, and medication)
Trial: 25654976
Drug: Peganum harmala
RxNorm normalized name: TITANIUM DIOXIDE 60 mg in 1 mL / ZINC OXIDE 60 mg in 1 mL TOPICAL CREAM [PHARMACA Natural Mineral Sunscreen SPF-30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peganum harmala L oil, applied 4 drops 3 times a day for 4 weeks
Trial: 24727261
Drug: Anti-vascular endothelial
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-vascular endothelial growth factor treatment
Trial: 24727261
Drug: Pro re
RxNorm normalized name: Blistex Pro Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro re nata treatment
Trial: 15932376
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate (INFP) 200 microg o.d.
Trial: 15932376
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (IHFP) 250 microg b.i.d.
Trial: 15932376
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INFP and IHFP
Trial: 8739595
Drug: HPMPC (cidofovir)
RxNorm normalized name: (S)-HPMPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMPC (cidofovir) at 1 mg/kg
Trial: 8739595
Drug: HPMPC (cidofovir)
RxNorm normalized name: (S)-HPMPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMPC (cidofovir) at 3 mg/kg
Trial: 8739595
Drug: HPMPC (cidofovir)
RxNorm normalized name: (S)-HPMPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMPC (cidofovir) at 10 mg/kg
Trial: 25738338
Drug: Mucograft (MG;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucograft (MG; a porcine‐derived purified collagen membrane)
Trial: 19460106
Drug: 100 mmol
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mmol L(‐1) butyrate
Trial: 19460106
Drug: 50 mmol
RxNorm normalized name: dibasic potassium phosphate 150 MMOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mmol L(‐1) butyrate
Trial: 17712121
Drug: MK‐0557 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐0557 1 mg/d plus sibutramine 10 mg/d
Trial: 17712121
Drug: MK‐0557 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐0557 1 mg/d plus orlistat 120 mg TID
Trial: 12809960
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg TID
Trial: 15117091
Drug: Lumiracoxib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 100 mg
Trial: 9543158
Drug: 375 IU
RxNorm normalized name: Ascorbic Acid/Biotin/Calcium/Calcium Pantothenate/Cholecalciferol/Chromium/Cyanocobalamin/Folic Acid/Iodine/Magnesium/Manganese/Molybdenum/Niacin/Potassium/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin E/Zinc 300 MG-0.15 MG-150 MG-0.05 MG-375 IU-1 MG-0.012 MG-0.15 MG-200 MG-10 MG-0.15 MG-20 MG-40 MG-150 MG-6 MG-3.9 MG-0.5 MG-3 MG-10500 IU-30 IU-15 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 IU urinary FSH, s.c., as a single injection on Day(LH+14) (group A; n = 11)
Trial: 9543158
Drug: 75 IU
RxNorm normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 IU daily from Day(LH+19) until Day(LH+23) (group B; n = 12)
Trial: 2973849
Drug: hANP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hANP infusion (2 pmol min‐1 kg‐1 for 3 h)
Trial: 20862469
Drug: Half-dose gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose gadolinium contrast
Trial: 20862469
Drug: Full-dose gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose gadolinium contrast
Trial: 18442632
Drug: Calorie restriction
RxNorm normalized name: Resurrection Lily Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie restriction mimetic therapy with metformin for 3 years
Trial: 16570675
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate 0.25% ointment
Trial: 10030325
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (diuretics, beta‐blockers)
Trial: 7946181
Drug: Isradipine monotherapy
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine monotherapy
Trial: 8767350
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Isradipine + metoprolol/enalapril)
Trial: 1879388
Drug: Social-influences-based drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social-influences-based drug prevention program (Midwestern Prevention Project)
Trial: 30019634
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 100 mg/day plus intensive blood pressure treatment (targeted systolic blood pressure < 120 mmHg, monitored with a home blood pressure measuring device)
Trial: 28490022
Drug: COPE (Concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE (Concurrent Treatment with Prolonged Exposure)
Trial: 28490022
Drug: RPT (Relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPT (Relapse Prevention Therapy)
Trial: 21131371
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 125 mg i.v.
Trial: 17022853
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg b.i.d. with Metformin 1000 mg b.i.d.
Trial: 17022853
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg b.i.d. with Sitagliptin placebo
Trial: 17022853
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg b.i.d. with Metformin placebo
Trial: 17022853
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of Sitagliptin and Metformin
Trial: 14618553
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg/d, flexibly dosed to 5-20 mg/d)
Trial: 14618553
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 mg/d, flexibly dosed to 5-20 mg/d)
Trial: 9589926
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy and aspirin (group I, n = 15)